Clinical trials: Paramyxoviridae Infections
Drug Safety
A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers
The purpose of the study is to assess the tolerability and safety of a range of repeated inhaled doses of MDT-637. This includes monitoring effects on pulmonary function and determination of blood levels of MDT-637 following…
- Trial name
- NCT01489306
- Testing
- MDT-637
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- MicroDose Therapeutx, Inc
Respiratory Syncytial Virus (RSV)
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies.
- Trial name
- Amélie (NCT06473519)
- Testing
- RSVpreF MDV, RSVpreF SDV
- Where
- 6 sites in United States
- Volunteers
- 453 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19 Respiratory Infection, Respiratory Syncytial Virus Infections
Infection Watch Study
This study will reach out to patients who have undergone diagnostic testing for the following respiratory illnesses from January 1st, 2018 to July 9th, 2023: COVID-19, Influenza, Rhinovirus, and Respiratory Syncytial Virus.
- Conditions
- COVID-19 Respiratory Infection, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Influenza Viral Infections
- Trial name
- NCT04623047
- Where
- United States
- Volunteers
- 10,034 people, healthy volunteers welcome
- Sponsor
- Duke University
Parainfluenza
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
- Trial name
- PIV (NCT01924793)
- Testing
- DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
- Where
- 23 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ansun Biopharma, Inc.
RSV Infection
An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)
This primary objective of this study is to describe the incidence of RSV infection in adult hematopoietic cell transplant recipients OR hematological malignancies patients in Tianjin HI.
- Trial name
- NCT06490549
- Testing
- RSV infection observation cohort
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Respiratory Syncytial Virus (RSV) Infection
Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.
- Trial name
- NCT02718937
- Testing
- BTA-C585 oral capsule
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Biota Pharma Europe Limited
RSV Infection, Covid19
Respiratory Syncytial Virus Infection May be More Dangerous in Neonate
Investigators aimed to compare clinical and radiographic markers between SARS-CoV-2 positive and RSV positive infants
- Trial name
- NCT04531735
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Dr. Behcet Uz Children's Hospital
Meningococcal Infections
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers
- Trial name
- NCT00626327
- Testing
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Where
- 90 sites in United States
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Measles
Early Waning of Maternal Measles and Meningitis C Antibodies
Maternal antibodies (measles and meningitis C) may wane in the first six months after birth. Geometric mean titers(GMTs) of measles and meningitis C. Follow-up on 0 month, 3rd month,5th month and 7th month after birth.
- Trial name
- EWMM (NCT02219061)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangzhou Center for Disease Control and Prevention
Respiratory Syncytial Virus Infection
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
To evaluate the safety, efficacy, pharmacokinetic (PK) characteristics and antiviral activity of different doses of Deuterium Hydrobromide for suspension in the treatment of respiratory syncytial virus infection in infants.
- Trial name
- NCT06206720
- Testing
- Deuremidevir Hydrobromide for Suspension
- Where
- 22 sites in China
- Volunteers
- 60 people
- Sponsor
- Vigonvita Life Sciences
Influenza A Infection, Influenza B Virus Infection
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly.
- Conditions
- Influenza A Infection, Influenza B Virus Infection, SARS CoV 2 Infection, RSV Infection
- Trial name
- NPA-DC (NCT06401720)
- Where
- 5 sites in Sweden
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Influenza, Respiratory Syncytial Viruses
The Respiratory Protection Effectiveness Clinical Trial
Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases.
- Conditions
- Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus
- Trial name
- ResPECT (NCT01249625)
- Testing
- N95 Respirator, Medical/surgical mask
- Where
- 7 sites in United States
- Volunteers
- 2,862 people
- Sponsor
- Johns Hopkins University
Respiratory Syncytial Virus Infection, Healthy Volunteers
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult…
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
- Trial name
- NCT06134648
- Testing
- RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 646 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles, Mumps
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
The purpose of this study is to demonstrate that an investigational refrigerated vaccine with measles, mumps, rubella, and varicella is well tolerated and has similar immune response when compared to a frozen vaccine with…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092430
- Testing
- V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Children <24 Months Hospitalized for RSV-related Lower Respiratory Tract Infection
Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral Prophylaxis
Hospitalization for RSV lower respiratory tract infections (LRTI) still occurs, including in infants having received nirsevimab/clesrovimab or born to mothers vaccinated with Abrysvo.
- Trial name
- SiRiUS (NCT07893652)
- Testing
- Prior exposure to prophylactic treatment with Abrysvo or nirsevimab/clesrovimab, Non-exposure to prior prophylactic treatment
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Syncytial Virus Infections, RSV Infection
RESCEU: Defining the Burden of RSV Disease
This observational study will determine the burden of RSV disease in at least 2000 healthy infants over 6 years until November 2026.
- Trial name
- NCT03698084
- Testing
- venepuncture, nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University of Oxford
Tuberculosis, Diphtheria
Evaluation of an Infant Immunization Encouragement Program in Nigeria
Previous studies have shown that a small incentive can have a large impact on health behaviors like vaccinating children. New Incentives, an international non-governmental organization (NGO), aims to boost demand for immunization…
- Conditions
- Tuberculosis, Diphtheria, Tetanus, Pertussis
- Trial name
- NCT03870061
- Testing
- All Babies Are Equal Initiative (conditional cash transfer program)
- Where
- 3 sites in Nigeria
- Volunteers
- 5,187 people, healthy volunteers welcome
- Sponsor
- GiveWell
Respiratory Syncytial Virus Infections
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.
- Trial name
- NCT06363370
- Testing
- Human interferon α1b Inhalation Solution
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Nipah Virus Infection
A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
- Trial name
- NCT05178901
- Testing
- PHV02
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
Respiratory Syncytial Virus Infections
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately…
- Trial name
- RSV OA=ADJ=012 (NCT06534892)
- Testing
- RSVPreF3 OA vaccine
- Where
- 251 sites in United States, Australia and 15 more
- Volunteers
- 10,212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline